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Abstract:  
Background & Aims: Colorectal cancer (CRC) incidence and mortality are higher in black 
vs white populations. The reasons for these disparities are not clear, yet some guidelines 
recommend screening black persons for CRC starting at ages 40–45 years. We performed a 
systematic review and meta-analysis to compare the prevalence of advanced adenomas (AAs) 
and advanced, precancerous colorectal neoplasms (ACNs) between asymptomatic black and 
white screen-eligible adults. 
 
Methods: We searched Ovid MEDLINE, PubMed, Embase, and the Cochrane Library to 
identify articles (published from 1946 through June 2017) that reported prevalence values of AA 
or ACN in average-risk black and white individuals undergoing screening colonoscopy. Two 
authors independently assessed study quality and risk for bias using a modified validated quality 
assessment instrument. Following the PRISMA guidelines, 2 authors independently abstracted 
descriptive and quantitative data from each study. We performed a random effects meta-analysis 
to determine risk differences and odds ratios (ORs). 
 
Results: From 1653 articles, we identified 9 studies for analysis, comprising 302,128 
individuals. Six of the 9 studies were of high methodological quality, had a low risk for bias, and 
were included in the meta-analysis. In these 9 studies, the overall prevalence values for AA and 
ACN did not differ significantly between back (6.57%) and white screened individuals (6.20%; 
OR, 1.03; 95% CI, 0.81–1.30). Among a subgroup of 5 studies, the prevalence of proximal AA 
and ACN was significantly higher in black (3.30%) than in white screened individuals (2.42%; 
OR, 1.20; 95% CI, 1.12–1.30). Excluding the largest study did not affect overall prevalence (OR, 
0.99; CI, 0.73–1.34) but eliminated the difference in prevalence of proximal AA or ACN (OR, 
1.48; 95% CI, 0.87–2.52). 
 
Conclusions: In a meta-analysis, we found the overall prevalence of AA and ACN did not differ 
significantly between average-risk black and white persons, indicating that the age at which to 
begin CRC screening need not differ based on race. 
 
 
Key words: colon cancer; incidence; ethnicity differences; colonoscopic detection 
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INTRODUCTION 
 
Although colorectal cancer (CRC) is the third most common cancer and the second-leading 
cause of cancer death in the U.S. among all racial/ethnic groups, higher CRC incidence and 
mortality rates are found among Black adults.1 In 2014, the U.S. incidence of colorectal cancer 
was 50.4 per 100,000 for Black men, as compared with 43.0 per 100,000 for White men 2. 
Incidence rates were lower for women, but were higher for Black women (38.9 per 100,000 
versus 32.8 per 100,000 for White women).2 A similar discrepancy exists for CRC mortality: 23.1 
per 100,000 for Black men vs.16.4 per 100,000 for White men, and 15.3 per 100,000 for Black 
women vs. 11.7 per 100,000 for White women.2 Because of the higher incidence and mortality 
rates in Blacks, the American College of Gastroenterology and the U.S. Multi-Society Task 
Force on Colorectal Cancer recommend CRC screening beginning at 45 years for average-risk 
Blacks, while the American College of Physicians recommends starting at age 40, five to ten 
years earlier than for non-Blacks.3-6 Several reasons for this racial disparity are offered. Some 
studies suggest genetic / biological differences, while others point to social, environmental, or 
behavioral differences, including disparities in rates of CRC screening.7-9  
 
The immediate precursor to CRC is the advanced adenoma (AA), the current target lesion for 
screening.3 AAs usually include an adenoma 1 cm or larger, or one with villous histology or 
high-grade dysplasia, regardless of size. This combination of findings is also referred to as 
advanced precancerous polyps or neoplasms and sometimes includes sessile serrated polyps 1 
cm or larger. When AA or advanced, precancerous polyps are combined with CRC, the term 
“advanced colorectal neoplasia” or “advanced neoplasia” is used.  
 
The published literature comparing AA prevalence in Blacks and Whites is inconsistent. A 
difference in AA prevalence between Blacks and Whites could lend support to biology / genetics 
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as a contributor to the incidence / mortality disparity, whereas no difference would suggest non-
biological factors such as access to and uptake of screening, or behavioral or social differences 
in response to symptoms. The purpose of this systematic review was to compare the 
prevalence of AA or advanced, precancerous colorectal neoplasms (ACN) between Blacks and 
Whites. 
 
METHODS 
 
This study was conducted on the campus of Indiana University Purdue University at 
Indianapolis from May to August 2017 without the need for approval by the Institutional Review 
Board of Indiana University. We report methods and results consisted with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) format.10 
 
Data Sources and Searches.  A comprehensive search of the literature was performed by a 
medical librarian (TWE) using Ovid MEDLINE, PubMed, Embase, the full Cochrane Library, and 
ClinicalTrials.gov. Searches were performed in June 2017, and all databases were searched 
from inception.  Bibliographies of relevant studies were reviewed for additional references. 
Search strategies for the four databases are displayed in the Appendix. Database-specific 
subject headings and keyword variants for each of the four main concepts – colorectal disease, 
precancerous conditions, and the black and white populations – were identified and combined. 
Results were limited to the English language.   
 
Study Selection. We included studies measuring the prevalence of advanced adenomas (AA) 
or advanced colorectal neoplasia (CRC + AA) in average-risk Blacks and Whites undergoing 
screening colonoscopy. 
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Data Extraction and Quality Assessment. Two authors independently abstracted descriptive 
and quantitative information from the studies. Study quality and risk of bias were assessed 
using a modified version of the National Institute of Health’s Quality Assessment Tool for 
Observational Cohort and Cross-Sectional Study.11 This instrument was modified to make it 
more relevant for cross-sectional research, resulting in the need to assess each article for 9 of 
the instrument’s 14 questions.11 Thus, study quality could range from 0 to 9. Disagreements in 
ratings were resolved in discussion. The quality criteria for the modified tool are found in the first 
column of Table 1.  
 
Data Synthesis and Analysis. Study homogeneity was quantified using the I2 statistic, which 
quantifies the percent of variation across a group of studies that is due to heterogeneity rather 
than chance.12 A random effects model was used to combine data on AA/ACN prevalence from 
individual studies using R software and metafor R package for meta-analysis.13,14 Prevalence 
point estimates, and risk differences and odds ratios with 95% confidence limits were 
generated. A funnel plot and regression test for asymmetry for overall AA/ACN prevalence were 
generated to assess this body of literature for publication bias.15 Prior to performing the 
analyses, we decided to include two subgroup analyses based on study design features. In one 
subgroup analysis, we would exclude the largest study for two reasons: 1) it was the largest 
study by far and was expected to have a large and numerically-important influence on 
aggregate risk estimates; 2) it was the only study without polyp histology. The second subgroup 
analysis would include the studies with highest study quality and lowest risk for bias 
 
Role of the Funding source. The study was funded by the Indiana CTSI Collaboration in 
Translational Research Grants. The funding source had no role in the study’s design, conduct of 
the review, or reporting. 
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RESULTS 
 
A total of 1653 references were identified. After removal of 128 duplicates, 1525 unique titles 
and abstracts were reviewed. From 1525 titles, we excluded 1363 for various reasons (Figure 
1) and reviewed 162 full text articles. Of the 162 articles, 153 were excluded (Figure 1), leaving 
9 studies that met all inclusion criteria and no exclusion criteria.16-24 
 
Descriptive characteristics of the 9 studies are shown in Table 2. The 9 articles included 
302,128 participants and were published between 2010 and 2017. Individual study sample sizes 
ranged from 80 to 292,494. The objective of 7 studies was to quantify the prevalence of 
advanced adenomas in both racial groups.  All studies were cross-sectional, 5 of which 
collected data prospectively.16,19,21-23 Six studies involved single sites,16-18,20-22 while the 
remaining three19,23,24 were multisite studies, one of which19 included 84 practices throughout the 
U.S.  All study populations were average-risk. The criteria for advanced adenoma were 
comparable across studies except for the largest study, which used “polyp > 9 mm” without 
including polyp histology.19 For this analysis, we assumed that all such polyps were advanced 
adenomas. One study did not provide a definition for advanced adenoma. Large serrated polyps 
were included in the definition of advanced adenoma in two studies.20,23 All studies defined 
“proximal” as the splenic flexure and colon segments proximal to it. Six studies reported no 
differences in AA prevalence between Blacks and Whites, 1 study reported a higher AA 
prevalence in Whites, 1 study reported higher prevalence in Blacks, and 1 reported a higher 
prevalence of large polyps in Blacks. 
 
Study quality was generally high, with scores between 7 and 9, out of a highest achievable 
score of 9 (Table 1). Six of 9 studies were of high methodological quality, with low-risk for 
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bias.17-21,23 The three studies with high-risk for bias16,22,24 did not adjust prevalence for age and 
sex, a critical feature for a valid comparative analysis.  
 
Advanced adenoma (AA) / advanced colorectal neoplasia (ACN). Among the 9 studies, 
prevalence of AA/ACN ranged from 2% to 10% for Whites and 5% to 12% for Blacks (Table 3). 
Results of individual studies for AA/ACN are shown in Figure 2a.  Only the study by Lieberman 
and colleagues,19 for which no histology was available, showed a higher prevalence of AA/ACN 
in Blacks. The study by Schroy and colleagues21 showed that Whites had a higher prevalence of 
AA/ACN. In aggregate, however, there was no difference in AA/ACN prevalence between 
Blacks and Whites, with respective point prevalences of 6.57% and 6.20%, an odds ratio of 1.03 
(95% CI, 0.81-1.30) and absolute risk difference of 0.00 (95% CI, -0.01 to 0.02) (Table 3). The I2 
values indicate moderate heterogeneity among studies. These findings remained unchanged 
with the largest study19 excluded and in the subgroup of 5 studies17,18,20,21,23 (“best subset”) in 
which the results in each individual study were adjusted for age and sex (Table 3). I2 values for 
these two subgroups reflect low-to-moderate study heterogeneity.   
 
Proximal AA/ACN.  Among the 5 studies in which advanced proximal lesions were 
measured,16,18,19,21,23 the prevalence ranged from 0% to 4% for Whites and from 2% to 9% for 
Blacks.  Individual study results for proximal AA/ACN are shown in Figure 2b. Two18,19 of 5 
studies showed greater prevalence in Blacks, one of which was the study by Lieberman and 
colleagues.19 In aggregate, due to the dominance of the Lieberman study, proximal AA/ACN 
was more common among Blacks, with point prevalences of 3.30% in Blacks and 2.42% in 
Whites, an odds ratio of 1.20 (95% CI, 1.12-1.30), and absolute risk difference of 0.01 (95% CI, 
0.00 to 0.01). The I2 test showed no study heterogeneity (0%). Exclusion of the Lieberman study 
increased heterogeneity to the low-to-moderate range and eliminated the difference in proximal 
AA/ACN prevalence, but with less precision: OR= 1.48; 95% CI, 0.87-2.52) and risk difference 
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of 0.007 (95% CI, -0.004 to 0.018). In the best subset of 3 studies 18,21,23, which had a moderate 
degree of heterogeneity, there was no difference in prevalence: OR=1.44 (CI, 0.84-2.49), risk 
difference of 0.006 (CI, -0.005 to 0.018) (Table 3). A funnel plot for overall prevalence of 
AA/ACN did not suggest publication bias (P=0.52) (Figure 3). 
 
DISCUSSION 
 
In this systematic review of 9 studies of screening colonoscopy involving more than 300,000 
subjects, we found no difference in the prevalence of advanced precancerous neoplasia 
between Blacks and Whites. This main finding among all studies was maintained in subgroup 
analyses that excluded the largest study and included only the highest quality studies.  Further, 
five of the studies examined differences in the prevalence of advanced, precancerous neoplasia 
in the proximal colon, among which Blacks had a higher prevalence – an absolute risk 
difference of 1% and a 1.20 times greater odds than Whites. This small difference was not 
maintained in subgroup analyses.  Among all studies, the degree of heterogeneity by I2 test 
ranged from none to moderate.   
 
Our findings are consistent with most, but not all, of the previous studies on this topic. We 
applied specific inclusion and exclusion criteria to identify those studies in which colonoscopy 
was the screening modality used in average-risk Blacks and Whites. Study quality and risk for 
bias were assessed in a standard fashion using an adapted validated instrument and 
independent review by two study authors. Study quality was moderate to high, with only three 
studies having high-risk for bias resulting from lack of adjustment for demographic covariates of 
age and sex. The consistency of the quantitative findings for any advanced precancerous 
neoplasia suggest that the finding of no difference is robust. For proximal advanced 
precancerous neoplasia, the overall difference was clinically small and was not supported by 
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pre-specified subgroup analyses. In total, our findings indicate no differences in advanced, 
precancerous neoplasia between average-risk Black and White screen-eligible adults.  
Our findings are consistent with those from a VA-based, multi-site, retrospective, cross-sectional 
analysis of nearly 91,000 Veterans, in which the prevalence of CRC was slightly higher in 
Blacks (1.5% vs. 1.4% in Whites; adjusted OR=1.29; CI, 1.11-1.51) but with no difference in 
prevalence of advanced adenomas between Blacks and Whites (9.0% vs. 9.4%, respectively; 
adjusted OR=1.00; CI, 0.94-1.07).25  An analysis of CRC survival among Veterans extends the 
observation of “no difference” between Blacks and Whites, as Dominitz and colleagues 
compared outcomes in Black and White male veterans with a new diagnosis of CRC, finding no 
difference in rates of surgical resection, radiation, chemotherapy, or 5-year survival.26 Finally, 
the Delaware experience of resolution of the disparity in CRC incidence and mortality as the 
CRC screening disparity closed nicely illustrates how equalizing CRC screening rates between 
Blacks and Whites eliminated differences in CRC incidence, disease stage, and mortality.27  
 
This analysis has strengths and limitations that warrant comment. One strength is the large 
sample size, despite the fact that one study accounted for nearly 97% of the observations. 
Another strength is the specificity of the study selection process, which resulted in a clinically 
homogeneous body of literature for analysis that was low-to-moderate in its degree of statistical 
heterogeneity. Study quality was moderate to high, as determined by a validated instrument. 
Finally, the quantitative findings were consistent in subgroup analyses, suggesting robustness 
of the numerical findings. A limitation of this analysis is the lack of adjustment of prevalence 
estimates for age and race in three studies, covariates that may have created imbalance in 
prevalence estimates between Black and White subjects in these studies. As mentioned, 
however, results were stable in subgroup analysis, suggesting that any imbalances due to 
unadjusted demographic features were not clinically important.  A second limitation was the 
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inability to adjust for other factors associated with CRC and/or advanced neoplasia such as 
BMI, cigarette smoking, certain medications (NSAIDs, aspirin, statins) and other behavioral 
features, as these factors could further confound prevalence estimates. Publication bias is a 
potential third limitation, which we believe is unlikely, as the funnel plot does not support it, and 
six of nine studies show no difference in AA/ACN prevalence between Blacks and Whites.   
 
Based on our findings and those of other studies, a practical clinical issue is whether Blacks 
should be screened earlier than Whites, as some guideline organizations recommend.3,4,28 We 
found no difference between Blacks and Whites in the prevalence of AN, largely comprised of 
advanced precancerous polyps, which is the precursor lesion for most CRC. Absence of a 
difference in AN prevalence suggests that the differences in CRC incidence and mortality are 
less likely due to biology and more likely due to behavioral or sociocultural differences in 
recognition of symptoms, need for diagnostic evaluation, and/or access to, acceptance or 
uptake of preventive services. Our findings, along with other studies on this topic,17,29-33 
suggests that the age at which to begin screening need not differ based on race, especially in 
settings where obstacles to care are mitigated. However, for settings in which access to care 
disfavors Blacks, beginning screening in Blacks prior to age 50 may help mitigate this disparity. 
   
A final consideration is the recent recommendation by the American Cancer Society to start 
average-risk screening in everyone at age 45.34 If this recommendation is followed broadly, it 
would lessen the clinical and policy implications of our findings. However, the uptake of this 
recommendation is yet to be determined, as it differs from those of all other professional 
organizations.3-5  
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CONCLUSION 
 
In conclusion, we found no difference in the prevalence of advanced precancerous neoplasia 
between average-risk, screen-eligible Blacks and Whites who underwent screening 
colonoscopy. Further, among the most rigorous studies, there was no difference in advanced 
neoplasia in the proximal colon. In areas without disparities in access to screening, our findings 
support eliminating the age difference at which to begin average-risk screening that is currently 
recommended by some guideline organizations, and beginning average-risk screening at age 
50 regardless of race. To the extent that the advanced adenoma is the precursor lesion for 
CRC, tailoring the age at which to begin screening and how to screen based on race is not 
supported by our findings. 
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Table 1. Quality Criteria and Risk of Bias for Included Studies 
Quality Criteria Collazo, 
2015 16 
Friedenberg, 
2012 17 
Lebwohl, 
2012 18 
Lieberman, 
2014 19 
Mendelsohn, 
2017 20 
Schroy, 
2013 21 
Stein, 
2010 22 
Wallace, 
2016 23 
Xirasagar, 
2014 24 
Was the research question or objective 
clearly stated? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Was the study population clearly specified 
and defined? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Were all subjects selected or recruited from 
the same or similar populations (including 
the same time period)? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Were inclusion and exclusion criteria for the 
study prespecified and applied uniformly? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Was a sample size justification, power 
description, or variance and effect estimates 
provided? 
No Yes No No No Yes No No No 
Were age, sex, and race measured prior to 
the outcomes being measured? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Were age, sex, and race clearly defined, 
valid, reliable, and implemented 
consistently? 
Yes 
(self) 
Yes 
(self) 
Yes 
(self) 
Yes 
(endoscopists) 
 Yes (not 
stated) 
 Yes 
(not 
stated) 
Yes (not 
stated) 
Yes (not 
stated) 
Yes (not 
stated) 
Were the outcome measures clearly 
defined, valid, reliable, and implemented 
consistently? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Critical: Were groups comparable at 
baseline* or were differences in age and 
sex adjusted? 
No Yes Yes Yes Yes Yes No Yes No 
Point score: 7 9 8 8 8 9 7 8 7 
Risk of bias: high low low Low low low high low high 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
Table 2. Descriptive Information from Included Studies 
 
1st Author, 
Year (ref)
 
Study 
Objective
 
Study 
Design
 
Study 
Setting
 
Sample 
Size, n
 
Study Population
 
Primary Outcome
 
Covariates 
Adjusted 
For 
 
Findings
 
Comments
 
Collazo, 2015 
(16)
 
Report yield 
of SC based 
on 
demographics 
Prospective 
cross-
sectional 
study 
Single urban 
institution 
2004 to 
2011 
37 
Blacks 
and 43 
Whites 
Uninsured and 
underinsured average-
risk patients, age ≥50 
years, undergoing SC. 
Excluded: had a FOB 
test within past year, 
flexible sigmoidoscopy 
within 10 years, history 
of IBD, CRC, spoke 
languages other than 
English or Spanish  
AA (an adenoma ≥1 
cm in diameter, 
villous/tubulovillous 
histology, high-
grade dysplasia, or 
cancer), PAA 
(splenic flexure) 
None No 
difference 
in AA or 
PAA 
prevalence 
Small sample 
size, no 
adjustment for 
age and sex 
Friedenberg, 
2012 (17)
 
Determine 
and compare 
yield of AA 
and proximal 
location 
Retrospective 
cross-
sectional 
study 
Single urban 
institution 
2007 to 
2010 
669 
Blacks 
and 257 
Whites 
Average-risk, 
asymptomatic patients 
age 45 to 59 with a 
negative family history 
of CRC and complete 
SC with good/excellent 
preparation. Excluded: 
prior SC, colon 
adenomas, or IBD 
AA (an adenoma 
>10 mm in 
diameter, villous 
features or high-
grade dysplasia), 
proximal adenoma 
(splenic flexure) 
Age, sex, 
BMI, 
tobacco 
use, regular 
aspirin use, 
statin use 
No 
difference 
in AA 
prevalence 
Comparison 
group of white 
patients age 
45-49 was not 
available 
Lebwohl, 
2012 (18)
 
Measure 
adenoma 
prevalence 
Retrospective 
cross-
sectional 
study 
Single urban 
institution 
2006 to 
2010 
591 
Blacks 
and 
3542 
Whites 
Patients ≥50 years 
undergoing first-time 
colonoscopy. 
Excluded: incomplete 
or prior colonoscopy, 
poor bowel 
preparation, personal 
history of polyps, 
indications of occult GI 
blood loss, anemia, 
history of neoplasia, 
IBD, FAP or HNPCC 
AA (an adenoma 
≥10mm in greatest 
diameter or 
exhibiting advanced 
histology such as 
villous, tubulovillous 
or high grade 
dysplasia), PAA 
(splenic flexure) 
Age, sex, 
family 
history of 
colorectal 
neoplasia 
Blacks have 
a higher 
prevalence 
of AA and 
PAA than 
Whites  
29% of 
subjects were 
excluded due 
to missing 
data 
pertaining to 
race/ethnicity 
Lieberman, 
2014 (19)
 
Measure 
prevalence of 
significant 
polyps based 
on 
demographics 
Prospective 
cross-
sectional 
study 
84 practice 
sites in the 
US 2000 to 
2011 
17955 
Blacks 
and 
269160 
Whites 
Average-risk patients 
≥40 years undergoing 
screening 
colonoscopy. 
Excluded: family 
history of CRC or 
polyps, positive FOB 
Large polyps 
(polyps sized >9mm 
or described as a 
tumor); large 
proximal polyps 
(splenic flexure) 
Age, sex Blacks ≥50 
have a 
higher 
prevalence 
of large 
polyps and 
large 
No histology 
of polyps 
(poor 
surrogate of 
ACN), did not 
state how 
polyps were 
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test, or any other lower 
GI symptoms  
proximal 
polyps than 
whites 
measured, 
endoscopist 
determined 
race 
Mendelsohn, 
2017 (20)
 
Compare 
adenoma 
yield 
Retrospective 
cross-
sectional 
study 
Single urban 
institution, 
time period 
not stated 
191 
Blacks 
and 199 
Whites 
Average-risk, 
underserved patients 
40 to 69 years of age 
undergoing SC 
Adherence to 
screening, any 
adenoma, AA (no 
definition given) 
Age, sex, 
education, 
smoking, 
NSAID use, 
obesity 
No 
difference 
in AA 
prevalence 
Modest 
sample size, 
did not state 
how race was 
obtained 
Schroy, 2013 
(21)
 
Define 
prevalence 
and location 
of ACN 
Prospective 
cross-
sectional 
study 
Single urban 
institution 
2005 to 
2012 
1681 
Blacks 
and 
1172 
Whites 
Asymptomatic, 
average-risk patients 
aged 50 to 79 
undergoing SC. 
Excluded: prior polyps, 
family history of CRC, 
poor bowel 
preparation, or 
incomplete 
examination 
Serrated lesions, 
ACN (a tubular 
adenoma ≥10mm, 
villous features or 
high-grade 
dysplasia, 
dysplastic serrated 
lesion of any size, 
or invasive cancer), 
proximal ACN 
(splenic flexure) 
Age, sex, 
education, 
insurance, 
risk factors 
Whites 
have a 
higher 
prevalence 
of ACN 
than 
Blacks. No 
difference 
in proximal 
ACN 
prevalence 
Did not state 
how race was 
obtained 
Stein,  2010 
(22) 
Determine if 
BMI is 
associated 
with ACN in a 
diverse cohort 
Prospective 
cross-
sectional 
study 
Single 
suburban 
site 2006 to 
2007 
67 
Blacks 
and 356 
Whites 
Asymptomatic patients 
aged ≥40 years 
undergoing SC. 
Excluded: GI 
symptoms, prior 
history of colonic 
neoplasia, IBD, prior 
endoscopic screening 
in 10 years 
ACN (large ≥1cm 
adenoma, villous 
adenoma (>25% 
villous, high grade 
dysplasia or cancer) 
None No 
difference 
in ACN 
prevalence 
No 
adjustment for 
age and sex; 
did not state 
how race was 
obtained 
Wallace, 
2016 (23)
 
Assess 
prevalence of 
large bowel 
polyps within 
a diverse 
population 
Prospective 
cross-
sectional 
study 
Regional 
study 2011 
to 2013 
110 
Blacks 
and 91 
Whites 
Uninsured, 
asymptomatic patients 
with no personal 
history of colorectal 
neoplasia between the 
ages 45 to 64. 
Excluded: unable to 
speak English or 
cognitively unable to 
provide informed 
consent 
Serrated histology, 
AA (adenomas with 
at least 25% villous 
component, high 
grade dysplasia, or 
an estimated size of 
≥1cm), PAA (splenic 
flexure) 
Age, sex, 
clinical site 
No 
difference 
in AA or 
PAA 
prevalence 
Relatively 
small sample 
size and did 
not state how 
race was 
obtained 
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Xirasagar, 
2014 (24)
 
Evaluate the 
racial 
disparities 
reduction 
potential of a 
program for 
indigent 
persons 
Retrospective 
cross-
sectional 
study 
Multi-site 
urban site 
2009 to 
2010 
465 
Blacks 
and 163 
Whites 
Uninsured patients 
with income <200% of 
the federal poverty 
limit, age 45-64 years 
undergoing SC. 
Excluded: GI 
symptoms 
ACN (adenoma 
≥10mm, villous / 
tubulovillous 
features, high-grade 
dysplasia, or 
cancer) 
None No 
difference 
in ACN 
prevalence 
No 
adjustment for 
age and sex. 
did not state 
how race was 
obtained 
 
AA = advanced adenoma; PAA = proximal advanced adenoma; CRC = colorectal cancer; SC = screening colonoscopy; FOB = fecal occult blood; IBD = inflammatory bowel 
disease; HNPCC = hereditary non-polyposis colorectal cancer; BMI = body mass index; FAP = familial adenomatous polyposis 
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Table 3. Summary of Study Results 
 
      
Prevalence  
Range 
Prevalence  
Point Estimate 
     
 Outcome Study 
N 
Subject 
N 
Blacks Whites Blacks Whites Risk 
Difference 
(95% CI) 
Odds 
Ratio 
(95% CI) 
I2 test 
Risk Difference 
(RD), Odds Ratio 
(OR) 
AA/ACN          
 
All studies 9 296,749 5-12% 2-10% 6.57% 6.20% 0.00 (-0.01 to 
0.02) 
 1.03 
(0.81 to 
1.30) 
51.9% (RD) 
55.9% (OR) 
Moderate 
All studies 
except 
Lieberman 2014   
8 9634 5-12% 2-10% 5.95% 6.11% -0.001  
(-0.183 to 
0.017) 
0.99 
(0.73 to 
1.34) 
39.2% (RD)  
44.5% (OR)  
Moderate 
Best subset† 5 8503 5-12% 4-9% 5.78% 5.79% 0.002 (-0.018 
to 0.022) 
1.06 
(0.75 to 
1.50) 
49.8% (RD)  
53.5% (OR) 
Moderate 
Proximal AA/ACN          
 
All studies 5 299,761 2-9% 0-4% 3.30% 2.42% 0.01 (0.00 to 
0.01) 
 1.20 
(1.12 to 
1.30) 
0% (RD)  
0% (OR) 
Low 
 
All studies 
except 
Lieberman, 2014 
4 7267 2-9% 0-4% 2.64% 1.93% 0.007 (-0.004 
to 0.018) 
1.48 
(0.87 to 
2.52) 
20.4% (RD)  
38.0% (OR) 
Low to moderate 
 
Best subset* 3 7187 2-9% 1-4%  3.57% 2.07% 0.006 (-0.005 
to 0.018) 
1.44 
(0.84 to 
2.49) 
27.4% (RD)  
47.4% (OR)  
Moderate 
 
†Best subset includes references 17, 18, 20, 21, 23 
*Best subset included references 18, 21, 23
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Figure Legend 
 
Figure 1. Study Selection Flow Chart 
Figure 2: A. Forest Plot for Advanced Adenoma – All studies;  
Figure 2: B. Forest Plot for Proximal Advanced Adenoma – All Studies 
Figure 3: Funnel Plot for Advanced Adenoma – All studies. 
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Appendix: Detailed Search Strategies 
 
 
MEDLINE (Ovid):  
1      exp Colonic Polyps/  
2      exp Cecal Diseases/ or exp Colonic Diseases/ or exp Rectal Diseases/  
3      exp Intestine, Large/  
4      exp Colonoscopy/  
5      exp Adenomatous Polyps/  
6      Adenoma/ or adenoma*.tw.  
7      Precancerous Conditions/  
8      exp Carcinoma in Situ/  
9      (precancer* or pre cancer* or preneoplas* or pre neoplas* or premalignan* or pre 
malignan* or dysplas*).tw.  
10      (advanced or size* or distribution* or location*).tw.  
11      (cancer related or malignant transformation).tw.  
12     Mass Screening/  
13      exp "Early Detection of Cancer"/  
14      (or/1-4) and (or/5-13)  
15      exp African Continental Ancestry Group/  
16      (black* or african american* or negro* or afro*).tw.  
17      exp European Continental Ancestry Group/  
18      (caucasian* or white*).tw.  
19      exp *African Continental Ancestry Group/  
20      (black* or african american* or negro* or afro*).ti.  
21      ((15 or 16) and (17 or 18)) or 19 or 20  
22      14 and 21  
23      limit 22 to english language 
24      exp Animals/ not exp Humans/  
25      23 not 24  
 
PubMed (PubMed.gov):  
#1 colon [tiab] OR colonic [tiab] OR colorectal [tiab] OR "colo rectal" [tiab] OR colonoscop* [tiab] 
#2 adenoma* [tiab] OR precancer* [tiab] OR pre cancer* [tiab] OR preneoplas* [tiab] OR pre 
neoplas* [tiab] OR premalignan* [tiab] OR pre malignan* [tiab] OR dysplas* [tiab] OR screen* 
[tiab] 
#3 advanced [tiab] OR size* [tiab] OR distribution* [tiab] OR location* [tiab] OR "cancer related" 
[tiab] OR "malignant transformation" [tiab] OR “carcinoma in situ” [tiab] 
#4 black* [tiab] OR african american* [tiab] OR negro* [tiab] OR afro* [tiab] 
#5 caucasian* [tiab] OR white* [tiab] 
#6 black* [ti] OR african american* [ti] OR negro* [ti] OR afro* [ti] 
#7 (#1 AND (#2 OR #3) AND ((#4 AND #5) OR #6)) Filters: English 
#8 (#7 NOT medline [sb]) 
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EMBASE (Embase.com):  
#1  'large intestine tumor'/exp 
#2  'large intestine disease'/exp 
#3  'large intestine'/exp 
#4  'colonoscopy'/exp 
#5  'colorectal carcinogenesis'/exp 
#6  'colon adenomatosis'/exp 
#7  'adenomatous polyp'/exp 
#8  'precancer and cancer-in-situ'/exp 
#9  'early cancer diagnosis'/exp 
#10  precancer*:ti,ab OR (pre NEXT/1 cancer*):ti,ab OR preneoplas*:ti,ab OR 
(pre NEXT/1 neoplas*):ti,ab OR premalignan*:ti,ab OR (pre NEXT/1 malignan*):ti,ab 
OR dysplas*:ti,ab OR adenoma*:ti,ab 
#11  advanced:ti,ab OR size*:ti,ab OR distribution*:ti,ab OR location*:ti,ab OR 'cancer related':ti,ab 
OR 'malignant transformation':ti,ab 
#12  'cancer screening'/exp 
#13  (#1 OR #2 OR #3 OR #4 OR #5 OR #6) AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12) 
#14  'black person'/exp 
#15  black*:ti,ab OR (african NEXT/1 american*):ti,ab OR negro*:ti,ab OR afro*:ti,ab 
#16  'caucasian'/exp 
#17  caucasian*:ti,ab OR white*:ti,ab 
#18  'black person'/exp/mj 
#19  black*:ti OR (african NEXT/1 american*):ti OR negro*:ti OR afro*:ti 
#20  ((#14 OR #15) AND (#16 OR #17)) OR #18 OR #19 
#21  #13 AND #20 AND [english]/lim 
 
Cochrane Library (Wiley):   
#1 (colon or colonic or colorectal or colo next rectal or colonoscop*):ti,ab,kw  
#2 (precancer* or pre next cancer* or preneoplas* or pre next neoplas* or premalignan* 
or pre next malignan* or dysplas* or screen* or adenoma*):ti,ab,kw  
#3 (advanced or size* or distribution* or location* or "cancer related" or "malignant 
transformation" or "carcinoma in situ"):ti,ab,kw  
#4 (black* or african next american* or negro* or afro*):ti,ab,kw  
#5 (caucasian* or white*):ti,ab,kw  
#6 (black* or african next american* or negro* or afro*):ti  
#7 #1 and (#2 or #3) and ((#4 and #5) or #6)  
 
